Revenue reached USD 12.59 billion in Q2 2026, up 13.00 percent. Abbott Laboratories stock was EUR 92

Abbott Laboratories is a global health care company. Founded in 1888, the company operates in four main segments: established pharmaceutical products, diagnostic products, nutritional products—including infant formula—and medical devices. As of 2024, Abbott’s medical devices segment was its largest and fastest-growing, accounting for about 45% of revenue. That segment includes devices for monitoring cardiovascular health, glucose monitoring systems for diabetes care, and neuromodulation devices for chronic pain and movement disorders.

Abbott Laboratories recently launched Ensure Max Protein 3-in-1 Muscle Support, gained FDA approval for expanded CardioMEMS HF System app capabilities, and began U.S. commercialization of the SimpleScreen CRC blood-based colorectal cancer screening test. These product moves show Abbott Laboratories using the breadth of its nutrition, cardiology and diagnostics platforms to address muscle health, heart failure management and cancer screening at the same time. This article examines how Abbott...

Abbott Laboratories (NYSE:ABT) has been identified as a leading group advancing closed-loop neurostimulation in bioelectronic medicine devices. The company is highlighted for closed-loop neurostimulation systems that interact with neural signals to modulate treatment in real time. This focus on bioelectronic medicine complements Abbott

Rate hikes are back on the table and fuel driven inflation is squeezing both households and corporate budgets, yet some large US dividend stocks still aim to offer a measure of calm when markets feel jumpy. Investors scanning for resilient income now risk missing pockets of quality hiding in plain sight. This piece walks through three defensive large caps exposed to the latest Fed and inflation headlines, and explains why they merit a closer look today. The stocks covered next are a sample...

Revenue hit USD 12.59 billion in the second quarter, up 13.00 percent. Abbott Laboratories stock cos

Revenue rose 13.00 percent to USD 12.59 billion in the second quarter. Abbott Laboratories stock cos

Abbott trades at a 18x forward P/E with $7.4B in free cash flow, while Intuitive Surgical commands a 39x multiple backed by zero debt and 20% revenue growth.

Abbott Laboratories (NYSE:ABT) offers investors access to several segments of the healthcare industry, including diabetes care, medical devices, and diagnostics. The company also boasts a long record ...

Abbott Laboratories (NYSE:ABT) launched Ensure Max Protein 3-in-1 Muscle Support, combining protein, creatine, and HMB in one product. The group also brought SimpleScreen CRC, a blood-based colorectal cancer screening assay, to market as part of its diagnostics portfolio. Abbott received FDA approval for new patient-facing digital features connected to its CardioMEMS heart failure monitoring system. The Ensure Max Protein 3-in-1 Muscle Support launch sits within wider shifts in Abbott's...

Abbott Laboratories (NYSE:ABT) offers investors access to several segments of the healthcare industry, including diabetes care, medical devices, and diagnostics. The company also boasts a long record of raising its dividends, which is why it deserves consideration for investors who are looking for both income and long-term growth. That does not mean that a company with […]

Abbott has a low-risk profile with significant upside potential.

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

Abbott Laboratories (NYSE:ABT) introduced Ensure Max Protein 3-in-1 Muscle Support, a combined protein, creatine, and HMB powder. The product is NSF certified and targets muscle building, recovery, and preservation for everyday active consumers and athletes. This launch expands Abbott